| Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment | 2018/02/01 | English | 189 |
| Long Noncoding RNAs in Cancer: From Function to Translation | 2015/10/01 | English | 183 |
| Super-Enhancer-Driven Transcriptional Dependencies in Cancer | 2017/04/01 | English | 180 |
| Targeting Transcription Factors in Cancer | 2015/09/01 | English | 177 |
| The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies | 2017/01/01 | English | 174 |
| Polytherapy and Targeted Cancer Drug Resistance | 2019/03/01 | English | 170 |
| The Immune Biology of Microsatellite-Unstable Cancer | 2016/03/01 | English | 168 |
| Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine | 2016/01/01 | English | 167 |
| Clinical Development of BRAF plus MEK Inhibitor Combinations | 2020/09/01 | English | 166 |
| ALTernative Telomere Maintenance and Cancer | 2015/10/01 | English | 165 |
| The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer | 2018/02/01 | English | 165 |
| The Evolving Landscape of Brain Metastasis | 2018/03/01 | English | 162 |
| Exosomes as a Multicomponent Biomarker Platform in Cancer | 2020/09/01 | English | 159 |
| Cancer Epigenetics, Tumor Immunity, and Immunotherapy | 2020/07/01 | English | 155 |
| Necroptosis and tumor progression | 2022/01/01 | English | 151 |
| Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities | 2016/02/01 | English | 149 |
| Gluconeogenesis in Cancer: Function and Regulation of PEPCK, FBPase, and G6Pase | 2019/01/01 | English | 148 |
| Resisting Resistance: Targeted Therapies in Lung Cancer | 2016/07/01 | English | 147 |
| Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates | 2018/02/01 | English | 143 |
| Modeling Pancreatic Cancer with Organoids | 2016/04/01 | English | 141 |
| Targeting Glycosylation: A New Road for Cancer Drug Discovery | 2020/09/01 | English | 140 |
| Hypoxia: Signaling the Metastatic Cascade | 2016/06/01 | English | 140 |
| Microfluidics: A New Tool for Modeling Cancer–Immune Interactions | 2016/01/01 | English | 137 |
| The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View | 2020/03/01 | English | 136 |
| Necroptosis and Cancer | 2017/04/01 | English | 134 |
| SASP: Tumor Suppressor or Promoter? Yes! | 2016/11/01 | English | 133 |
| Gut Microbiota in Cancer Immune Response and Immunotherapy | 2021/07/01 | English | 128 |
| Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy | 2017/08/01 | English | 128 |
| The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy | 2017/09/01 | English | 127 |
| Targeting EMT in Cancer with Repurposed Metabolic Inhibitors | 2020/11/01 | English | 124 |